Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Pituitary Neoplasms 4Nelson Syndrome 2Multiple Myeloma 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prostatic Neoplasms 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Meningioma 1Lymphoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulinoma 1Hyperinsulinism 1

Interventions

Cyclophosphamide 41fludarabine 35Tacrolimus 28Mycophenolic Acid 27Whole-Body Irradiation 25Busulfan 24fludarabine phosphate 21Melphalan 19thymoglobulin 16Antilymphocyte Serum 16Methotrexate 13Thiotepa 12Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 9Filgrastim 8Cyclosporine 8trametinib 7Sirolimus 7Nivolumab 5ruxolitinib 4merphos 4Peripheral Blood Stem Cell Transplantation 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Bendamustine Hydrochloride 4tocilizumab 3itacitinib 3fedratinib 3dabrafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Neoplasms × pasireotide × Clear all
NCT02215070 2021-11-17

Pasireotide in Prevention of GI Toxicity

Duke University

Phase 2 Completed
37 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡